Author

A. Krishnan

Observed names: A Krishnan, A Y Krishnan, A. Y. Krishnan, Ayana Krishnan

Observed institutions: Roswell Park Comprehensive Cancer Center, City Of Hope National Medical Center, Kaiser Permanente, Emory University, Duke University, Moffitt Cancer Center, Bristol-Myers Squibb (United States), City of Hope, Dana-Farber Cancer Institute, Kosan Biosciences (United States)

ORCID: 0000-0001-9716-3284

Observed ORCID: 0000-0001-9716-3284

OpenAlex ID: A5035985145

Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study

2008 · A. Goy, S.H. Bernstein, et al. · Annals of Oncology · 336

PDF

A long-term follow-up report on allogeneic stem cell transplantation for patients with primary refractory acute myelogenous leukemia: impact of cytogenetic characteristics on transplantation outcome

2003 · H.C Fung, A Stein, et al. · Transplantation and Cellular Therapy · 119

Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time

2017 · S K Kumar, A Dispenzieri, et al. · Leukemia · 92

Equivalence of 2 effective graft-versus-host disease prophylaxis regimens: Results of a prospective double-blind randomized trial

2000 · N.J. Chao, D.S. Snyder, et al. · Transplantation and Cellular Therapy · 81

Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study

2010 · S K Kumar, I Flinn, et al. · Leukemia · 80

Autologous hematopoietic cell transplantation for multiple myeloma patients with renal insufficiency: a center for international blood and marrow transplant research analysis

2017 · A Mahindra, P Hari, et al. · Bone Marrow Transplantation · 65

Second transplants for multiple myeloma relapsing after a previous autotransplant—reduced-intensity allogeneic vs autologous transplantation

2013 · C O Freytes, D H Vesole, et al. · Bone Marrow Transplantation · 57

Conditional survival and cause-specific mortality after autologous hematopoietic cell transplantation for hematological malignancies

2012 · A M VanderWalde, C-L Sun, et al. · Leukemia · 49

Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation

2015 · G L Uy, L J Costa, et al. · Bone Marrow Transplantation · 39

Multi-Center Phase II Study of Perifosine (KRX-0401) Alone and in Combination with Dexamethasone (dex) for Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Promising Activity as Combination Therapy with Manageable Toxicity.

2007 · Paul Richardson, S. Lonial, et al. · Blood · 39

Hematologic Aspects of HIV/AIDS

2001 · Alexandra M. Levine, David T. Scadden, et al. · Hematology · 38

Maintenance thalidomide following single cycle autologous peripheral blood stem cell transplant in patients with multiple myeloma

2006 · F Sahebi, R Spielberger, et al. · Bone Marrow Transplantation · 36

Cyclosporine and mycophenolate mofetil prophylaxis with fludarabine and melphalan conditioning for unrelated donor transplantation: a prospective study of 22 patients with hematologic malignancies

2004 · R Rodriguez, P Parker, et al. · Bone Marrow Transplantation · 26

Reduced-intensity allogeneic stem cell transplantation for patients whose prior autologous stem cell transplantation for hematologic malignancy failed

2003 · H.C Fung, S Cohen, et al. · Transplantation and Cellular Therapy · 24

PDF

Should HIV-positive patients with lymphoma be offered stem cell transplants?

2003 · A Krishnan, J Zaia, et al. · Bone Marrow Transplantation · 22

Tanespimycin plus bortezomib in patients with relapsed and refractory multiple myeloma: Final results of a phase I/II study

2009 · P. G. Richardson, A. Chanan-Khan, et al. · Journal of Clinical Oncology · 20

Phase II Trial of SCIO-469 as Monotherapy (M) or in Combination with Bortezomib (MB) in Relapsed Refractory Multiple Myeloma (MM).

2006 · David S. Siegel, A. Krishnan, et al. · Blood · 20

Phase I/II Report from a Multicenter Trial of Perifosine (KRX-0401) + Bortezomib in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma Previously Treated with Bortezomib.

2007 · Paul Richardson, A. Jakubowiak, et al. · Blood · 18

Phase 1 Clinical Trial of KOS-953 + Bortezomib (BZ) in Relapsed Refractory Multiple Myeloma (MM).

2005 · Asher Alban Chanan-Khan, P. G. Richardson, et al. · Blood · 15

A Multicenter Phase II Study of Perifosine (KRX-0401) Alone and in Combination with Dexamethasone (Dex) for Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM).

2006 · Paul Richardson, S. Lonial, et al. · Blood · 13

Defibrotide (DF) for the Treatment of Severe Veno-Occlusive Disease (sVOD) and Multi-Organ Failure (MOF) Post SCT: Final Results of a Multi-Center, Randomized, Dose-Finding Trial.

2006 · Paul Richardson, R.J. Soiffer, et al. · Blood · 11

The outcome of ZBEAM, a regimen combining 90Y ibritumomab tiuxetan with high dose chemotherapy in elderly patients with non-Hodgkin’s lymphoma (NHL)

2005 · A. Y. Krishnan, A. Nademanee, et al. · Journal of Clinical Oncology · 10

Tanespimycin (T) + bortezomib (BZ) in multiple myeloma (MM): Pharmacology, safety and activity in relapsed/refractory (rel/ref) patients (Pts)

2007 · P. G. Richardson, A. Chanan-Khan, et al. · Journal of Clinical Oncology · 9

Autologous stem cell transplant (ASCT) for AIDS-related lymphoma (ARL)

2009 · A Krishnan, J Zaia, et al. · Infectious Agents and Cancer · 7

PDF

Defibrotide (DF) for the Treatment of Severe Veno-Occlusive Disease (VOD) and Multi-System Organ Failure (MOF) Post SCT: Final Results of a Phase II, Multicenter, Randomized Study and Preliminary Analyses of Surrogate Markers and Ultrasound Findings.

2004 · Paul G. Richardson, R. J. Soiffer, et al. · Blood · 3

Works count: 43

Citation count: 1,241

H-index: 18

I10-index: 22